Trevi Therapeutics, Inc.
No enriched coverage for $TRVI in the last 7 days.
No SEC Form 4 filings for $TRVI in the last 30 days.
See all $TRVI insider activity →Simply Wall St reports Trevi Therapeutics (TRVI) has started Phase 3 and Phase 2B chronic cough trials and says it has about $188M in cash, cash equivalents and marketable securities at year-end 2025, supporting a runway into 2028. The article cites TRVI shares at $18.50 and a fair value narrative of $26.18.
Trevi Therapeutics, Inc. (TRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase
Analysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
Recent TRVI coverage spans financial news, technology and earnings.
Trial kickoff and stated funding runway support a bullish re-rating narrative, but the article flags ongoing losses and possible dilution risk.
The filing updates the Haduvio clinical timeline and extends cash runway into 2030, which can re-rate probability-weighted trial outcomes and near-term financing risk.
Initiation can move the stock if investors treat it as a proxy for upcoming catalysts, but the article provides no such catalyst details.
The article ties TRVI’s near-term momentum to fresh, conference-delivered clinical efficacy messaging for Haduvio and outlines next Phase 2b timing.
Positive Phase 2 data for Haduvio is a near-term catalyst for Trevi’s refractory chronic cough program, potentially improving sentiment and trial expectations.
alphai scores every news story that mentions TRVI with an AI model for sentiment and relevance, and aggregates insider trades from Trevi Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Simply Wall St reports Trevi Therapeutics (TRVI) has started Phase 3 and Phase 2B chronic cough trials and says it has about $188M in cash, cash equivalents and marketable securities at year-end 2025, supporting a runway into 2028. The article cites TRVI shares at $18.50 and a fair value narrative of $26.18.
6 min readTrevi Therapeutics, Inc. (TRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 trvi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase
7 min readAnalysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
2 min readTrevi Therapeutics (NASDAQ:TRVI) shares rose 9.85% to $19.07 after management highlighted clinical results for Haduvio, an extended-release nalbuphine oral treatment for refractory chronic cough (RCC) and idiopathic pulmonary fibrosis (IPF). The company cited a $14B to $15B chronic cough market by 2035. It plans a Phase 2b trial in 2H 2026.
5 min readGSK plc reported phase III results for camlipixant, a P2X3 receptor antagonist, from the Calm-1 and Calm-2 trials. According to GSK, the Calm-1 trial met its primary endpoint, with 50 mg twice daily reducing 24-hour cough frequency versus placebo at week 12. GSK’s walk-away from the program also highlighted Trevi Therapeutics’ Haduvio, which had positive phase II data in June.
4 min readTrevi Therapeutics shares rose 13.10% to $19.64 after the company presented clinical data on Haduvio (nalbuphine extended-release) for chronic cough at the European Respiratory Society Cough Conference in London. Trevi said results show a statistically significant cough-frequency reduction across IPF-related and refractory chronic cough. Analysts cited a $21.10 average target; Trevi also reported a June $162 million net offering.
6 min readTrevi Therapeutics (NASDAQ: TRVI) has scheduled an End-of-Phase 2 meeting with the FDA in Q1 2026 to discuss its chronic cough program for idiopathic pulmonary fibrosis (IPF) patients, focusing on its investigational therapy Haduvio. The company plans to initiate a Phase 2b trial for refractory chronic cough in H1 2026 and expects to launch its Phase 3 program for nalbuphine ER in the IPF patient population in H1 2026. Despite being pre-revenue, Trevi boasts a strong financial position, with significant stock performance gains and positive analyst outlooks.
2 min readHC Wainwright & Co. has reiterated its 'Buy' rating for Trevi Therapeutics (TRVI), maintaining a price target of $21.00, signaling confidence in the company's future growth. This follows a series of positive analyst ratings from various firms in late 2025, which also raised price targets. Trevi Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing Haduvio for chronic cough indications and prurigo nodularis.
2 min readTrevi Therapeutics (NASDAQ:TRVI) is set to meet with the FDA in Q1 2026 to discuss its chronic cough program for idiopathic pulmonary fibrosis (IPF) and plans a Phase 2b trial for refractory chronic cough in H1 2026. The company, which is pre-revenue but has seen significant stock gains and strong financial positioning, is developing Haduvio (oral nalbuphine ER), which has shown a statistically significant reduction in cough frequency. Analysts have issued "Buy" ratings and price targets, indicating potential upside, as the company addresses a significant unmet medical need for chronic cough in IPF and non-IPF interstitial lung disease patients.
4 min readTrevi Therapeutics, Inc. announced strategic updates for its investigational therapy Haduvio™ (oral nalbuphine ER) in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The company is scheduled for an FDA End-of-Phase 2 meeting in Q1 2026 for its IPF program and plans to initiate a Phase 2b trial for RCC in H1 2026. These updates precede their participation in the 15th Annual LifeSci Partners Corporate Access Event during the J.P. Morgan Healthcare Conference.
4 min read
